Xenon Pharmaceuticals Inc. (NASDAQ:XENE) Given Consensus Recommendation of “Buy” by Brokerages

Xenon Pharmaceuticals Inc. (NASDAQ:XENE) has been assigned an average recommendation of “Buy” from the eighteen ratings firms that are currently covering the stock, MarketBeat Ratings reports. One analyst has rated the stock with a sell recommendation, fifteen have issued a buy recommendation and two have assigned a strong buy recommendation to the company. The average 12 month target price among brokerages that have issued ratings on the stock in the last year is $75.6875.

XENE has been the subject of several analyst reports. Guggenheim reaffirmed a “buy” rating and issued a $90.00 price objective on shares of Xenon Pharmaceuticals in a research note on Monday, March 9th. Needham & Company LLC reduced their price target on Xenon Pharmaceuticals from $80.00 to $78.00 and set a “buy” rating on the stock in a report on Friday, May 8th. Wolfe Research started coverage on Xenon Pharmaceuticals in a report on Monday, February 23rd. They issued an “outperform” rating and a $60.00 price target on the stock. Bank of America reiterated a “buy” rating on shares of Xenon Pharmaceuticals in a report on Monday, March 9th. Finally, Robert W. Baird increased their price target on Xenon Pharmaceuticals from $63.00 to $97.00 and gave the stock an “outperform” rating in a report on Monday, March 9th.

Xenon Pharmaceuticals Price Performance

NASDAQ:XENE opened at $55.00 on Wednesday. The firm has a market capitalization of $5.32 billion, a price-to-earnings ratio of -11.70 and a beta of 0.65. Xenon Pharmaceuticals has a 1 year low of $28.19 and a 1 year high of $63.95. The business has a 50 day simple moving average of $55.33 and a 200-day simple moving average of $46.89.

Xenon Pharmaceuticals (NASDAQ:XENE) last posted its quarterly earnings data on Thursday, May 7th. The biopharmaceutical company reported ($1.17) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($1.17). During the same period in the prior year, the business earned ($0.83) earnings per share. As a group, analysts expect that Xenon Pharmaceuticals will post -4.87 earnings per share for the current fiscal year.

Insider Transactions at Xenon Pharmaceuticals

In other news, CEO Ian Mortimer sold 7,308 shares of the stock in a transaction that occurred on Friday, March 13th. The stock was sold at an average price of $55.23, for a total value of $403,620.84. Following the sale, the chief executive officer directly owned 19,923 shares in the company, valued at approximately $1,100,347.29. This represents a 26.84% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, insider Andrea Difabio sold 1,342 shares of the stock in a transaction that occurred on Friday, March 13th. The stock was sold at an average price of $55.23, for a total value of $74,118.66. Following the completion of the sale, the insider owned 7,301 shares in the company, valued at approximately $403,234.23. The trade was a 15.53% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last three months, insiders have sold 296,707 shares of company stock worth $17,845,365. 4.07% of the stock is currently owned by company insiders.

Institutional Trading of Xenon Pharmaceuticals

Several institutional investors and hedge funds have recently modified their holdings of the stock. Goldman Sachs Group Inc. increased its holdings in Xenon Pharmaceuticals by 7.9% during the 1st quarter. Goldman Sachs Group Inc. now owns 442,732 shares of the biopharmaceutical company’s stock worth $14,854,000 after purchasing an additional 32,486 shares during the period. Jump Financial LLC purchased a new position in Xenon Pharmaceuticals during the 2nd quarter worth $532,000. Sei Investments Co. purchased a new position in Xenon Pharmaceuticals during the 2nd quarter worth $711,000. The Manufacturers Life Insurance Company purchased a new position in Xenon Pharmaceuticals during the 2nd quarter worth $816,000. Finally, Alliancebernstein L.P. increased its holdings in Xenon Pharmaceuticals by 14.2% during the 2nd quarter. Alliancebernstein L.P. now owns 1,518,527 shares of the biopharmaceutical company’s stock worth $47,530,000 after purchasing an additional 189,141 shares during the period. Institutional investors own 95.45% of the company’s stock.

Key Stories Impacting Xenon Pharmaceuticals

Here are the key news stories impacting Xenon Pharmaceuticals this week:

• Positive Sentiment: JPMorgan raised Xenon Pharmaceuticals’ price target to $80 from $77 and maintained an Overweight rating, signaling about 45% upside from the recent stock price.
• Positive Sentiment: HC Wainwright increased earnings estimates for multiple years, including FY2026 through FY2030, while keeping a Buy rating and $74 target, suggesting improved long-term outlook.
• Neutral Sentiment: Short-interest data showed no meaningful short position change, offering little clear directional impact on the shares.
• Neutral Sentiment: Recent commentary on Xenon’s valuation after Phase 3 X TOLE2 success and an extended cash runway may be reinforcing investor confidence, but it was more interpretive than a direct company announcement. Article Title

About Xenon Pharmaceuticals

Xenon Pharmaceuticals Inc is a clinical?stage biopharmaceutical company dedicated to discovering and developing novel, small?molecule drugs targeting ion channels in the central and peripheral nervous system. The company’s research focus centers on neurological and pain disorders—including epilepsy, migraine, and neuropathic pain—by modulating key ion?channel proteins to restore normal neuronal function. Xenon’s scientific platform draws upon advances in ion?channel biology and structure?based drug design to identify and optimize therapeutic candidates with the potential for improved safety and efficacy profiles compared with existing treatments.

The company’s pipeline comprises multiple preclinical and clinical programs.